There is no universal peptide panel. A useful baseline matches the compound, the reason for taking it, your health history, and the result your clinician plans to watch.
Short answer
Discuss CBC, CMP, glucose or HbA1c, and lipids as a general starting point. Add compound-specific tests only when they have a clear job. For tesamorelin, that includes glucose and IGF-1.
Medical note: This is a discussion guide, not a lab order or clearance to start a drug. A licensed clinician should choose and interpret testing in the context of your diagnoses, medications, symptoms, and the exact product being considered.
01
First principle
Start with the compound, not a giant lab bundle.
The word peptide covers prescription medicines, compounded products, and substances sold for research use. A baseline for a semaglutide prescription has a different job from monitoring a growth hormone-releasing drug such as tesamorelin. A broad panel ordered without a question can produce noise, false alarms, and results nobody intended to act on.
Before the blood draw, ask one blunt question: what would make us delay the start, change the plan, or monitor more closely? Every test should connect to one of those decisions.
02
General baseline
Four panels often form the starting conversation.
These tests describe different parts of your current health. They are common starting points, not a mandatory package for every person or every peptide.
Red cells, white cells, hemoglobin, hematocrit, and platelets.
A general blood-cell baseline when your history, symptoms, or treatment plan gives it a reason. A CBC does not measure kidney function, liver enzymes, glucose, or hormones.
Glucose, electrolytes, calcium, proteins, liver-related markers, BUN, and creatinine.
A compact look at kidney function, liver-related markers, glucose, and fluid or electrolyte balance. A clinician may choose a BMP when the liver-related portion is not needed.
Glucose at one point in time plus an estimate of average blood glucose over roughly two to three months.
A metabolic baseline when the treatment, diagnosis, or personal risk makes glycemic change relevant. HbA1c can be misleading in some blood disorders, so it still needs clinical interpretation.
Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
A cardiovascular and metabolic reference when weight, diabetes, liver health, or a growth-hormone pathway is part of the clinical question.
The National Library of Medicine explains what a CBC, CMP, HbA1c test, and lipid panel measure. Your ordering clinician decides which ones fit.
03
Compound-specific
The useful add-ons come from the mechanism and the label.
tirzepatide
peptides
04
Research data
What our paper database says to pay
attention to.
Our research database does not contain a universal checklist. It does show which markers clinical researchers chose when they needed to measure a peptide drug’s metabolic effect or safety.
Researchers measured fasting glucose, an oral glucose tolerance test, HbA1c, home glucose, IGF-1, and lipids. That list supports glucose, HbA1c, IGF-1, and lipids as meaningful comparators for this mechanism. It does not make them the right panel for every peptide.
Clemmons et al., PLOS One, 2017 · PMID 28617838A 12-month trial studying hepatic fat named glucose as its primary safety endpoint and followed fasting glucose and HbA1c. That design is a useful reminder that a safety marker should be selected before treatment, not after a symptom or abnormal result appears.
Stanley et al., The Lancet HIV, 2019 · PMID 31611038The primary endpoint was change in HbA1c from baseline to 40 weeks. A baseline becomes useful when the same marker is measured again on a planned schedule and interpreted beside symptoms, medications, and dose changes.
Frías et al., New England Journal of Medicine, 2021 · PMID 34170647Research note: these records came from The Peptide App’s PubMed research dataset. We checked the paper abstracts against their PubMed records and used FDA labeling for monitoring language. The papers describe study measurements; they do not issue a personal lab order.
05
Skip the noise
More tests do not automatically make the plan safer.
Broad hormone panels, cortisol, tumor markers, pancreatic enzymes, and thyroid tests need a clinical reason. Ordering them because they appear in a social-media checklist can leave you with incidental abnormalities and no plan for what comes next.
Even a test that appears near a drug warning may have limited value as routine screening. Current tirzepatide labeling says routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of medullary thyroid carcinoma. Your personal or family history still matters, and the medication is contraindicated for some histories. The point is to let the label and clinician guide the decision instead of adding every available test.
06
Before the draw
Make the baseline clean enough to compare later.
- Confirm whether any ordered test requires fasting.
- List prescriptions, supplements, and recent dose changes.
- Tell the clinician about illness, dehydration, hard training, and poor sleep that may affect results.
- Complete the baseline before the first dose whenever the clinician wants a true pre-treatment comparison.
- Use the same lab and similar conditions for follow-up when practical.
- Save the report date, reference ranges, and the plan for when to repeat it.
Once the clinician sets the plan, keep the compound, schedule, dose changes, symptoms, and follow-up dates together. Our peptide protocol tracking guide shows how to build that record without relying on memory.
07
Questions for the appointment
Bring a short list, not a screenshot of somebody else’s panel.
- Which result would stop or delay this treatment?
- Which marker should move if the treatment is doing its job?
- Which safety marker needs a repeat, and when?
- What symptoms should trigger testing sooner?
- How do my current medications change the plan?
faq
Baseline lab questions
There is no universal peptide blood panel. A clinician may start with a CBC, CMP, fasting glucose or HbA1c, and a lipid panel when those tests fit your health history and the reason for treatment. The specific compound can add more useful tests, such as IGF-1 for tesamorelin or another therapy that acts on the growth hormone axis.
Only when the peptide acts on a hormone pathway or your symptoms and history give the test a clinical reason. A broad hormone bundle is not a standard prerequisite for every peptide. Ask which result would change the decision to start, delay, or monitor treatment.
FDA labeling for tesamorelin calls for glucose evaluation before and during therapy and IGF-1 monitoring during therapy. The exact baseline and follow-up schedule belongs with the prescribing clinician.
For patients with diabetes, current semaglutide labeling calls for blood-glucose monitoring before treatment and during treatment. Kidney function may matter based on existing disease and if vomiting, diarrhea, or another reaction could cause dehydration. A prescriber may also use HbA1c and other metabolic labs to establish a meaningful baseline.
No. Normal bloodwork cannot establish a product’s identity, dose accuracy, sterility, or purity, and it cannot replace human safety data that do not exist. FDA has identified potential safety risks and limited safety information for several substances sold as peptides, including BPC-157 and ipamorelin acetate.
